R3X1.F OCUPHIRE PHARMA DL-0001
- Market cap
- EUR 352M
- P/E
- -
- P/B
- 10.84x
- ROE
- -416.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is R3X1.F undervalued?
Graham numberThe Graham number of OCUPHIRE PHARMA DL-0001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OCUPHIRE PHARMA DL-0001 fundamental analysis
No fundamental analysis for OCUPHIRE PHARMA DL-0001 yet.
OCUPHIRE PHARMA DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OCUPHIRE PHARMA DL-0001
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-…
Full company profileOCUPHIRE PHARMA DL-0001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
OCUPHIRE PHARMA DL-0001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 589K | 39.9M | 19.0M | 11.0M | 14.2M | 5.40M |
| Operating Income | -22.7M | 18.2M | -10.6M | -34.1M | -38.6M | -66.8M |
| EBITDA | - | 18.2M | -8.64M | -57.5M | -48.1M | -159M |
| Net Income | -56.7M | 17.9M | -9.99M | -57.5M | -49.6M | -160M |
| EPS | -3.01 | 0.86 | -0.42 | -1.82 | -0.71 | -1.67 |
| Balance Sheet | ||||||
| Total Assets | 26.1M | 49.0M | 53.9M | 36.9M | 50.2M | 95.3M |
| Total Liabilities | 3.86M | 2.75M | 4.04M | 30.1M | 34.9M | 56.9M |
| Shareholders' Equity | 22.2M | 46.2M | 49.9M | 6.72M | 15.3M | 38.4M |
| Cash & Short-term Investments | 24.5M | 42.6M | 50.5M | 30.3M | 45.1M | 89.0M |
| Cash Flow | ||||||
| Operating Cash Flow | -19.4M | 14.3M | -1.11M | -25.6M | -35.3M | -51.6M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -19.4M | 14.3M | -1.11M | -25.6M | -35.3M | -51.6M |
| Ratios | ||||||
| ROE | -255.1% | 38.7% | -20.0% | -855.6% | -323.1% | -416.8% |
| ROA | -217.4% | 36.5% | -18.5% | -156.1% | -98.7% | -168.1% |
| Net Profit Margin | -9,625.3% | 44.9% | -52.4% | -523.4% | -349.3% | -2,966.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
OCUPHIRE PHARMA DL-0001 dividends
OCUPHIRE PHARMA DL-0001 has not paid dividends in the last 5 fiscal years.
Who owns OCUPHIRE PHARMA DL-0001
- Insiders 10.44%
- Institutions 60.85%
- Public & others 28.71%
- Shares outstanding 96.7M
- Free float 75.7M
OCUPHIRE PHARMA DL-0001 company profile
- Company name
- OCUPHIRE PHARMA DL-0001
- Ticker
- R3X1.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 27
- Fiscal year end
- December
- Address
- 8 Davis Drive, Durham, NC, United States, 27713
- Phone
- 984 884 6030
- Website
- opusgtx.com
About OCUPHIRE PHARMA DL-0001
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.
OCUPHIRE PHARMA DL-0001 management
10- Dr. George Magrath M.B.A., M.D., M.S.CEO & Director · born 1985
- Dr. Benjamin R. Yerxa Ph.D.President & Director · born 1966
- Mr. Joseph K. Schachle MBAChief Operating Officer · born 1965
- Mr. Robert E. Gagnon CPA, M.B.A.CFO & Principal Accounting Officer · born 1974
- Mr. Chris ErnstChief Technology Officer
- Dr. Andrew Murphy Ph.D.Chief Scientific Officer
- Ms. Jenny KobinInvestor Relations Officer
- Mr. Bernhard Hoffmann M.B.A.Senior Vice President of Corporate Development & Secretary · born 1956
- Ms. Amy Zaremba Rabourn C.P.A., MAccHead of Financial Quality Assurance · born 1981
- Ms. Bindu ManneHead of Market Development & Commercialization